FDA Approved Orzeyful, Replacing What Narcolepsy Type 1 Patients Lack
The August 5, 2026 approval of oveporexton brings the first orexin receptor agonist to market — wakefulness restored, not stimulated. What patients should ask.
Health News
Sector news category — verified health events only (FDA, guidelines, major studies)
FDA Approved Lipfendra, the First Oral PCSK9 Inhibitor, for High LDL
The July 15, 2026 approval of enlicitide turns an injection class costing thousands per year into a daily pill. Trial numbers, coverage questions, what's next.
FDA Approved Utebzi, the First Oral Carbapenem, for Complicated UTIs
The June 17, 2026 approval of tebipenem lets some kidney-infection patients leave the infusion chair for a pill — if stewardship rules hold the line on use.
FDA Approved Hepcludex, Closing the US Gap in Hepatitis D Treatment
The May 22, 2026 approval of bulevirtide brings the entry-blocker used in Europe since 2020 to US adults with chronic hepatitis delta. Who should be tested.
FDA Approved Veppanu for the Mutation That Ends Hormone Therapy's Run
The May 1, 2026 approval of epdegestrant targets ESR1-mutated HR-positive metastatic breast cancer. Why genomic testing at relapse decides who qualifies.
FDA Approved Foundayo: the Oral GLP-1 That Rewrites Obesity Drug Economics
The April 1, 2026 approval of orforglipron brings GLP-1 weight-loss therapy to a daily tablet manufactured at standard scale. Efficacy, side effects, coverage.